CTOs on the Move

Umoja Biopharma

www.umoja-biopharma.com

 
Umoja is developing a new approach to cancer therapy that retools a patient`s immune system in vivo, enhancing the body`s natural capacity to fight cancer. We envision a world where all patients with cancer have access to the most advanced immunotherapies and are free from the burdens of traditional cancer therapies.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Umoja Biopharma raised $53M on 11/18/2020
Umoja Biopharma raised $210M on 06/15/2021

Similar Companies

Supply Chain Logistics

Supply Chain Logistics is a Utica, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Paragon Laboratories

Paragon Laboratories is a Torrance, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Monticello Drug Company

Monticello Drug Company is a Jacksonville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AlliancePharma

The vision of AlliancePharma Inc. is to offer a service that is human, professional and personalized, and fosters the development of the skills of the replacement pharmacists and pharmacy technicians. In the long term, AlliancePharma Inc. strives to increase and improve the value of its privileged position in the area of pharmacy replacement services, as well as diversifying its activities in high value added sectors linked to health.

KemPharm

KemPharm is a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs that are designed to be improved versions of widely prescribed, approved drugs. Developing and encouraging a unique creativity, leveraged throughout the process of scientific discovery is the foundation of our corporate culture. At KemPharm we employ our Ligand Activated Therapy (LAT™) platform technology to create prodrugs that are new molecules which can improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety. We create new prodrugs by chemically attaching one or more molecules, or ligands, to an FDA-approved parent drug. When combined with the parent drug, our ligands create prodrugs designed to have improved drug attributes while maintaining efficacy equivalent to the parent drug. Once administered, targeted human metabolic processes, such as those in the GI tract, separate the ligand from the prodrug and release the parent drug, which can then exert its therapeutic effect. KemPharm has employed its LAT™ prodrug platform to create a diverse pipeline of prodrug therapeutics that target large market opportunities in pain, attention deficit hyperactivity disorder (ADHD) and other central nervous system indications.